PT Bundamedik Tbk (BMHS.JK)
IDR 246.0
(2.5%)
IDR 246.0
(2.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 223.9 Billion IDR | -32.9% |
| 2022 | 344.13 Billion IDR | -32.61% |
| 2021 | 570.28 Billion IDR | 95.49% |
| 2020 | 265.85 Billion IDR | 68.45% |
| 2019 | 155.81 Billion IDR | 23.84% |
| 2018 | 122.52 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 69.06 Billion IDR | -6.06% |
| 2024 Q2 | 51.74 Billion IDR | -25.28% |
| 2024 Q3 | 19.17 Billion IDR | -2.37% |
| 2023 Q3 | 50.72 Billion IDR | 58.95% |
| 2023 FY | - IDR | -32.9% |
| 2023 Q4 | 71.45 Billion IDR | 40.88% |
| 2023 Q2 | 31.91 Billion IDR | -46.04% |
| 2023 Q1 | 59.13 Billion IDR | -24.31% |
| 2022 Q2 | 89.95 Billion IDR | 14.53% |
| 2022 Q1 | 78.53 Billion IDR | 35.5% |
| 2022 FY | - IDR | -32.61% |
| 2022 Q4 | 78.13 Billion IDR | -0.78% |
| 2022 Q3 | 78.74 Billion IDR | -12.46% |
| 2021 Q2 | 145.56 Billion IDR | -0.03% |
| 2021 Q4 | 57.96 Billion IDR | -56.63% |
| 2021 Q3 | 133.64 Billion IDR | -8.19% |
| 2021 Q1 | 145.61 Billion IDR | 141.58% |
| 2021 FY | - IDR | 95.49% |
| 2020 FY | - IDR | 68.45% |
| 2020 Q1 | 36.18 Billion IDR | 0.0% |
| 2020 Q4 | 60.27 Billion IDR | -48.98% |
| 2020 Q3 | 118.14 Billion IDR | 226.47% |
| 2020 Q2 | 36.18 Billion IDR | -0.0% |
| 2019 FY | - IDR | 23.84% |
| 2018 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Metro Healthcare Indonesia Tbk | -7.68 Billion IDR | 3015.385% |
| PT Medikaloka Hermina Tbk | 1584.42 Billion IDR | 85.868% |
| PT Mitra Keluarga Karyasehat Tbk | 1555.38 Billion IDR | 85.604% |
| PT Murni Sadar Tbk | 155.6 Billion IDR | -43.893% |
| PT Famon Awal Bros Sedaya Tbk | 443.01 Billion IDR | 49.458% |
| PT Royal Prima Tbk | 52.4 Billion IDR | -327.24% |
| PT Kedoya Adyaraya Tbk | 61.12 Billion IDR | -266.33% |
| PT Sarana Meditama Metropolitan Tbk | 323.18 Billion IDR | 30.719% |
| PT Siloam International Hospitals Tbk | 2692.46 Billion IDR | 91.684% |
| PT Sejahteraraya Anugrahjaya Tbk | 437.22 Billion IDR | 48.789% |